Full Year 2023 Investor Presentation

16 Investor presentation Full year 2023 Financial outlook for 2024 Sales growth - at CER Expectations 31 January 2024 18% to 26% Sales growth - reported Operating profit growth - at CER Around 1 percentage point lower 21% to 29% Operating profit growth - reported Financial items (net) Effective tax rate Free cash flow Around 2 percentage points lower Gain of around DKK 1.3 billion 19% to 21% DKK 64 to 74 billion Novo NordiskⓇ The financial outlook is based on an assumption of a continuation of the current business environment and given the current scope of business activities and has been prepared assuming that currency exchange rates remain at the level as of 26 October 2023 CER: Constant exchange rates Note: Changes since last highlighted in bold

View entire presentation